SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pauls Matthew

(Last)

(First)

(Middle)

900 NORTHBROOK DRIVE

SUITE 200

(Street)

TREVOSE

19053

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2018

3. Issuer Name and Ticker or Trading Symbol
Strongbridge Biopharma plc [ SBBP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	40,000⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	08/23/2015	08/23/2019	Common Stock	72,727	$8.06	D
Stock Option (Right to Buy)	08/23/2016	08/23/2019	Common Stock	72,727	$10.74	D
Stock Option (Right to Buy)	08/23/2017	08/23/2019	Common Stock	81,818	$13.43	D
Stock Option (Right to Buy)	⁽²⁾	05/26/2025	Common Stock	151,818	$15.71	D
Stock Option (Right to Buy)	⁽³⁾	05/26/2025	Common Stock	151,363	$15.71	D
Stock Option (Right to Buy)	⁽⁴⁾	05/26/2025	Common Stock	75,682	$15.71	D
Stock Option (Right to Buy)	⁽⁵⁾	05/26/2025	Common Stock	75,682	$15.71	D
Stock Option (Right to Buy)	⁽⁶⁾	02/26/2026	Common Stock	164,313	$3.94	D
Stock Option (Right to Buy)	⁽⁷⁾	02/23/2027	Common Stock	304,687	$2.9	D

Explanation of Responses:

1. All 40,000 ordinary shares are held in the form of restricted stock units.

2. This option vests in sixteen equal quarterly installments beginning August 26, 2015.

3. This option vests in sixteen equal quarterly installments beginning October 16, 2015.

4. This option becomes 100% exercisable on the date that is the last trading day in the period in which the Issuer's closing stock price on each of 20 consecutive trading days as reported on NASDAQ has been at least $33.66, provided this occurs on or before May 26, 2019.

5. This option becomes 100% exercisable on the date that is the one year anniversary of the date that is the last trading day in the period in which the Issuer's closing stock price on each of 20 consecutive trading days as reported on NASDAQ has been at least $33.66, provided this occurs on or before May 26, 2019.

6. This option vests in sixteen equal quarterly installments beginning May 26, 2016.

7. This option vests in sixteen equal quarterly installments beginning May 23, 2017.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Stephen J. Long, as attorney-in-fact	01/02/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.